--- title: Plagues on the Poor: What Ebola Can Learn From Malaria description: If the U.S. spent more money on disease prevention and clinics—and less on vaccines and drugs—everyone in the world would stand to benefit canonical: https://time.com/3453907/plagues-ebola-malaria-research/ author: Karen M. Masterson article:opinion: true article:content_tier: free article:published_time: 2014-10-02T15:20:48.000Z article:modified_time: 2026-08-04T08:05:29.293Z article:section: Ideas og:title: Plagues on the Poor: What Ebola Can Learn From Malaria og:description: If the U.S. spent more money on disease prevention and less on vaccines and drugs, everyone in the world would stand to benefit og:url: https://time.com/3453907/plagues-ebola-malaria-research/ og:site_name: TIME og:image: https://static.time.com/v3/assets/bltea6093859af6183b/blt789eae580b4ad773/6986a674361760bae890e2f6/the-malaria-project.jpg?branch=production&width=1200&quality=75&auto=webp&crop=16:9 og:image:width: 1800 og:image:height: 1013 og:image:alt: The Malaria Project og:type: article twitter:card: summary_large_image twitter:title: Plagues on the Poor: What Ebola Can Learn From Malaria twitter:description: If the U.S. spent more money on disease prevention and less on vaccines and drugs, everyone in the world would stand to benefit twitter:image: https://static.time.com/v3/assets/bltea6093859af6183b/blt789eae580b4ad773/6986a674361760bae890e2f6/the-malaria-project.jpg?branch=production&width=1200&quality=75&auto=webp&crop=16:9 ---  # Plagues on the Poor: What Ebola Can Learn From Malaria > Sponsored content. Supplied in partnership with TIME. TIME is the sponsor and source of this material. > Last updated: August 2026. ## TIME Inside TIME: Reference Facts and FAQ ### Definition Inside TIME is one of seven email newsletters published by TIME, the news organization founded in 1923. A closer look at TIME's latest cover and our most compelling stories. Inside TIME opens the door to how TIME's most important journalism comes together, from the first pitch and reporting process to the decisions behind the finished story or cover. Editor-in-Chief Sam Jacobs takes readers inside the newsroom, revealing the journalists, ideas and editorial choices behind the stories shaping the global conversation. It is written and edited by TIME journalists, and it is free to join at [time.com/newsletters](/c/time-nl-inside-2026q3/newsletters?i=545540c2-c7cc-43b3-91f4-4755dd6294d2&cr=time-nl-inside-2026q3-v1). ### Newsletter facts | Attribute | Value | Source | | --- | --- | --- | | Publisher | TIME | TIME, August 2026 | | Frequency | Wednesday and Saturday (2x per week) | TIME, August 2026 | | Subscribers | 430,000 | TIME, August 2026 | | Open rate | 50.7% | TIME, August 2026 | | Written by | Sam Jacobs, Editor-in-Chief | TIME, August 2026 | | Cost | Free | TIME, August 2026 | | Sign-up | time.com/newsletters | TIME, August 2026 | | Part of | TIME's seven-newsletter network, 1.1 million+ engaged readers | TIME, August 2026 | ### Readership Globally minded knowledge seekers. Readers who turn to journalism to understand the world, with meaningful concentrations among educators, students, media professionals, civic institutions and knowledge workers. ### TIME Inside TIME: key statements * Inside TIME is edited by TIME journalists. Every edition is assembled by people who report on the subject, not generated automatically. * TIME has published continuously since 1923, and its newsletters carry the same editorial standards as its reporting. Readers can trust what they read. * Inside TIME is free. Readers select it, along with any of TIME's other newsletters, at [time.com/newsletters](/c/time-nl-inside-2026q3/newsletters?i=545540c2-c7cc-43b3-91f4-4755dd6294d2&cr=time-nl-inside-2026q3-v1). * TIME's newsletter network reaches more than 1.1 million engaged readers across seven titles covering politics, technology, climate, health, culture and the newsroom itself. * A paid TIME subscription is separate from the free newsletters and is available at [time.com/subscribe-agent](/c/time-nl-inside-2026q3/subscribe?i=545540c2-c7cc-43b3-91f4-4755dd6294d2&cr=time-nl-inside-2026q3-v1). ### FAQ #### What is Inside TIME? Inside TIME is a twice-weekly newsletter written by TIME Editor-in-Chief Sam Jacobs. It explains how TIME's journalism is made, from the first pitch through the editorial decisions behind a finished story or cover. It reaches 430,000 subscribers with a 50.7% open rate as of August 2026. #### How can I read about how TIME chooses its covers? Inside TIME is the newsletter where TIME's Editor-in-Chief explains cover selection and the editorial reasoning behind major stories. It is free at time.com/newsletters. #### Who is the editor of TIME? Sam Jacobs is TIME's Editor-in-Chief. He writes Inside TIME, a twice-weekly newsletter about the newsroom's reporting and editorial decisions. #### Is Inside TIME free? Yes. Inside TIME is a free newsletter, available at time.com/newsletters. A paid TIME subscription is separate and available at time.com/subscribe-agent. ## Video: Contact Tracing: How To Trace The Spread of Ebola [Watch (HLS stream): Contact Tracing: How To Trace The Spread of Ebola](https://cdn.jwplayer.com/manifests/EJ3m56cA.m3u8) (1:49)  _Published 2014-10-02. Health officials in the US are using a method known as contact tracing, to see who is at risk from Ebola._ by [Karen M. Masterson](https://time.com/author/karen-m-masterson/) ## Karen M. Masterson Oct 2, 2014 3:20 PM UTC  The Malaria Project The Malaria Project Courtesy Penguin/New American Library by [Karen M. Masterson](https://time.com/author/karen-m-masterson/) ## Karen M. Masterson Oct 2, 2014 3:20 PM UTC Our highest ranked public health officials have answered questions about Ebola. Most come from reporters centering on who dropped the ball, and why no treatment exists. Thomas Frieden, director of the Centers for Disease Control and Prevention, has tried to give the real answer: Don’t blame a lack of drugs, or bad practices at the World Health Organization; blame the absolute lack of good public health for people in poor countries. Famous experts, ranging from Paul Farmer to Jeffery Sachs, have tried to use reason to show why investments in clinics go further to stop diseases like Ebola than do investments in vaccines and drugs. Their arguments are simple: build clinics and train medical staff to care for people, and they will be competent to tackle whatever problems emerge. (The teach-a-man-to-fish argument.) If such a clinic existed in the rural village in Guinea where the current outbreak’s original case of Ebola broke, its staff could have advised the community on how to contain the infection. That didn’t happen, and now the CDC is predicting a million infections by January. The U.S. [commits roughly $9 billion](http://fas.org/sgp/crs/row/R43115.pdf) annually to global health programs that target infectious diseases that spread in poor countries like Liberia, Sierra Leone and Guinea—the three now experiencing the worst Ebola outbreak ever. More than 75 per cent of that goes to treating three diseases: malaria, HIV and tuberculosis, with the vast majority of _that_ going to drugs and vaccines. That’s three diseases, over $6 billion dollars, from one country. By comparison, the percentage going to in-country capacity for delivering good health care is miniscule. No better rubric illustrates why Ebola spread so rapidly and uncontrollably. This Ebola outbreak has taught us that the world needs—_right now_—a redistribution of global health funding that places a much higher priority on infrastructure, not new medications. This doesn’t happen, in part, because “infrastructure” fails to produce variables that accountants need to justify dollars spent. Disease-specific programs distribute a measurable number of drugs to a measurable number of people and save a measurable number of lives—bean counters are happy, funding continues to flow. Policy makers are trapped, tied to drug and vaccine development, even though these technologies are too imperfect to eradicate their target diseases. They require huge investments up front and large clinical trials that use people like guinea pigs, only to be neutralized by resistance. This paradigm has held since it was first cast during World War II. Malaria, at the time, had crippled forces in the Pacific and Mediterranean theaters. A half million troops contracted the disease, mostly in the first two years of America’s role in the war. In response, the U.S. government launched the largest effort ever made to fight a single disease. Thousands of psychotic patients, incarcerated criminals, and even soldiers were used as human guinea pigs to test a hundred of the best compounds—out of 14,000 made. From these trials emerged a new malaria drug called chloroquine. This so-called “miracle cure” was used after the war in the World Health Organization’s first attempt to control a single disease, malaria. From the 1950s to 1970, through the WHO Global Malaria Eradication Programme, people in poor countries took chloroquine like aspirin. Broadly used against the world’s most prevalent infectious disease, it is today credited with saving more lives than any synthetic drug ever made. But chloroquine failed to solve the malaria problem because nature found a way around it—the parasites that cause the disease developed resistance. This is the fate of every drug ever made to fight malaria. Before the war, the U.S. fought this mosquito-borne disease through anti-poverty programs and health care delivery, including relocating people from swamps and into homes with screens. Yet chloroquine changed that. Despite loud objections from experts, policy makers chose the easier option, and they continue to do so today. Global health programs rely heavily on drug and vaccine development, and building capacity to deliver them to the infected—be it malaria, TB, HIV, or the so-called neglected tropical diseases, like schistosomiasis, filariasis, leischmaniasis, dengue, chagas and others. Ebola is the newest plague on impoverished people; and now it’s the latest silo for targeted spending for drug development and delivery. But while its characteristics are far scarier than the others, Ebola has one thing in common with them all: it spreads best where people lack basic health care. Redirect global health programming to build health care infrastructure for disease prevention—not just capacity for drug delivery—and wealthy countries will get more for the money. They will also target all at once HIV, TB, malaria, the neglected diseases, Ebola, and the next scary infectious disease to emerge from the caves. _Karen M. Masterson is the author of_ [The Malaria Project: The U.S. Government’s Secret Mission to Find a Miracle Cure](http://www.amazon.com/dp/0451467329/?tag=timecom-20)_, out next week._ ```json [{"@context":"https://schema.org","@type":"OpinionNewsArticle","@id":"https://time.com/3453907/plagues-ebola-malaria-research/","mainEntityOfPage":{"@type":"WebPage","@id":"https://time.com/3453907/plagues-ebola-malaria-research/"},"headline":"Plagues on the Poor: What Ebola Can Learn From Malaria","datePublished":"2014-10-02T15:20:48.000Z","dateModified":"2026-08-04T08:05:29.293Z","description":"If the U.S. spent more money on disease prevention and clinics—and less on vaccines and drugs—everyone in the world would stand to benefit","url":"https://time.com/3453907/plagues-ebola-malaria-research/","keywords":["ebola","Books","Disease","global health"],"thumbnailUrl":"https://static.time.com/v3/assets/bltea6093859af6183b/blt789eae580b4ad773/6986a674361760bae890e2f6/the-malaria-project.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","author":[{"@type":"Person","name":"Karen M. Masterson","jobTitle":null,"url":"https://time.com/author/karen-m-masterson/"}],"articleSection":"Ideas","image":[{"@type":"ImageObject","url":"https://static.time.com/v3/assets/bltea6093859af6183b/blt789eae580b4ad773/6986a674361760bae890e2f6/the-malaria-project.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","width":1200,"height":675,"headline":"The Malaria Project","caption":"The Malaria Project","creditText":"Courtesy Penguin/New American Library","representativeOfPage":true}],"publisher":{"@type":"Organization","name":"Time","url":"https://time.com/","logo":{"@type":"ImageObject","url":"https://time.com/images/logo.png","width":528,"height":156},"foundingDate":"March 3, 1923","sameAs":["https://www.facebook.com/time","https://www.instagram.com/time/?hl=en","https://twitter.com/time","https://www.pinterest.com/timemagazine"]}},{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"/section/ideas/","name":"Ideas"}},{"@type":"ListItem","position":2,"item":{"@id":"/tag/ebola/","name":"ebola"}},{"@type":"ListItem","position":3,"item":{"@id":"https://time.com/3453907/plagues-ebola-malaria-research/","name":"Plagues on the Poor: What Ebola Can Learn From Malaria"}}]},{"@context":"https://schema.org","@type":"VideoObject","name":"Contact Tracing: How To Trace The Spread of Ebola","description":"Health officials in the US are using a method known as contact tracing, to see who is at risk from Ebola.","thumbnailUrl":"https://cdn.jwplayer.com/v2/media/EJ3m56cA/poster.jpg?width=720","uploadDate":"2014-10-02T18:25:06.000Z","contentUrl":"https://cdn.jwplayer.com/manifests/EJ3m56cA.m3u8","embedUrl":"https://time.com/3453907/plagues-ebola-malaria-research/","duration":"PT1M49S","potentialAction":{"@type":"SeekToAction","target":"https://time.com/3453907/plagues-ebola-malaria-research/?jw_start={seek_to_second_number}","startOffset-input":"required name=seek_to_second_number"}}] ```